Unlike the targeted drugs utilized in the treatment of NSCLC, such as the EGFR-TKIs and ALK inhibitors, chemotherapeutic agents, including platinum, are usually applied to cancer patients without any specific gene target in mind, but instead are based on established response rates in previous trials. Here, ALK is linked to non-small cell lung carcinoma.